Fred R. Hirsch, MD, PhD

From long-term data to additional clinical trials, more is needed to better understand immunotherapy in lung cancer.

Fred R. Hirsch, MD, PhD, professor of medicine, professor in pathology, University of Colorado, CEO, IASLC, discusses unmet needs in the treatment of lung cancer.